Medical Condition News

RSS

The Joint Commission, AHA/ASA recognize HUP with Comprehensive Stroke Center Certification

The Hospital of the University of Pennsylvania (HUP) has been recognized by The Joint Commission and the American Heart Association/American Stroke Association (AHA/ASA) as meeting The Joint Commission's standards for Disease-Specific Care Comprehensive Stroke Center Certification, becoming the first center in Philadelphia and among a select few hospitals in the United States to be named as part of an elite group of providers focused on complex stroke care.

4 Jan 2013

Scientists demonstrate importance of Plvap gene in mammalian physiology

Dartmouth scientists have demonstrated the importance of the gene Plvap and the structures it forms in mammalian physiology in a study published in December by the journal Developmental Cell.

4 Jan 2013

Top-line results from Biogen Idec’s dexpramipexole Phase 3 trial on amyotrophic lateral sclerosis

Today Biogen Idec reported top-line results of EMPOWER, a Phase 3 trial investigating dexpramipexole in people with amyotrophic lateral sclerosis (ALS).

3 Jan 2013

Pfizer, Repligen sign licensing deal to advance spinal muscular atrophy program

Repligen Corporation announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

3 Jan 2013

Researchers analyze impact of 3 unexpected sex determination factors

So, is it a girl or a boy? This is the first question parents ask at the birth of an infant. Though the answer is obvious, the mechanism of sex determination is much less so. Researchers at the University of Geneva (UNIGE) attempt to shed light on this complex process by identifying the crucial role played by insulin and IGF1 and IGF2 growth factors, a family of hormones known for its role in metabolism and growth.

3 Jan 2013

FDA approves Abbott’s XIENCE Xpedition Everolimus Eluting Coronary Stent System

Abbott today announced that the XIENCE Xpedition Everolimus Eluting Coronary Stent System received U.S. Food and Drug Administration (FDA) approval and is launching immediately in the United States, providing physicians with a next-generation technology with the largest size matrix in the U.S. market.

3 Jan 2013

Celtaxsys commences CTX-4430 Phase 1 study to treat pulmonary inflammation

Celtaxsys, Inc., a private biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders, today announced the initiation of a first-in-human Phase 1 clinical study of CTX-4430, which blocks the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H).

3 Jan 2013

FDA clears Soft Tissue Regeneration’s STR GRAFT

Soft Tissue Regeneration, an early stage orthopedic device company that has developed a breakthrough tissue engineering platform used to regenerate ligaments and tendons, announced today that it has received FDA clearance to market its STR GRAFT, a biodegradable scaffold used for soft tissue augmentation and rotator cuff repair.

3 Jan 2013

Partin Tables to predict prostate cancer spread now updated

Prostate cancer experts at Johns Hopkins have developed an updated version of the Partin Tables, a tool to help men diagnosed with prostate cancer and their doctors to better assess their chance of a surgical cure. The updated tool, based on a study of more than 5,600 men treated at The Johns Hopkins Hospital from 2006 to 2011, is published in the Jan. 3 issue of the British Journal of Urology International.

3 Jan 2013

Itch-specific nerve cells in skin discovered by John Hopkins scientists

Johns Hopkins researchers have uncovered strong evidence that mice have a specific set of nerve cells that signal itch but not pain, a finding that may settle a decades-long debate about these sensations, and, if confirmed in humans, help in developing treatments for chronic itch, including itch caused by life-saving medications.

3 Jan 2013

Trovagene, MD Anderson partner to detect transrenal BRAF mutations in metastatic cancers

Trovagene, Inc., a developer of transrenal molecular diagnostics, announced that it has entered into a clinical collaboration with The University of Texas MD Anderson Cancer Center to detect transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers.

3 Jan 2013

A little extra fat could be protective

A review of almost 100 studies found that people who were overweight or slightly obese had a lower risk of dying compared to those considered "normal" weight.

3 Jan 2013

$Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer$

Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.

3 Jan 2013

18F-FDG PET/CT may become important distant staging modality in patients with breast cancer

New research published in the January issue of The Journal of Nuclear Medicine shows that 18F-fludeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) imaging offers significant prognostic stratification information at initial staging for patients with locally advanced breast cancer. When compared to conventional imaging, 18F-FDG PET/CT more accurately showed lesions in the chest, abdomen and bones in a single session, changing management for more than 50 percent of the patients in the study.

3 Jan 2013

Aerobic better than resistance training when it comes to weight and fat loss

A new study led by North Carolina researchers has found that when it comes to weight- and fat loss, aerobic training is better than resistance training. The study is believed to the largest randomized trial to directly compare changes in body composition induced by comparable amounts of time spent doing aerobic and resistant training, or both in combination, among previously inactive overweight or obese non-diabetic adults.

3 Jan 2013

Psychiatric patients at risk of hospitalization due to protected records

Medical centers that elect to keep psychiatric files private and separate from the rest of a person's medical record may be doing their patients a disservice, a Johns Hopkins study concludes.

3 Jan 2013

Gut bacterial communities play an integral role in protecting against human intestinal disorders

Instability in the composition of gut bacterial communities (dysbiosis) has been linked to common human intestinal disorders, including inflammatory bowel disease and colorectal cancer; however, it is unclear if dysbiosis can instigate disease or if it is a consequence of the underlying disorder.

3 Jan 2013

No significant difference in patient outcomes with RBC transfusions using lower threshold levels

The level at which red blood cells are transfused, a common treatment in clinical practice, is often deliberated among physicians. Guidelines for blood transfusion levels were only recently issued in March 2012 diminishing some of the debate. Today, in a new section called JAMA Clinical Evidence Synopsis, the Journal of the American Medical Association (JAMA), published a summary of the systematic review of the 19 clinical trials that compare higher versus lower hemoglobin thresholds in red blood cell transfusion.

3 Jan 2013

Improving research on BPA chemical may lead to better guidelines for human health

Following a three-year study using more than 2,800 mice, a University of Missouri researcher was not able to replicate a series of previous studies by another research group investigating the controversial chemical BPA. The MU study is not claiming that BPA is safe, but that the previous series of studies are not reproducible.

3 Jan 2013

Kareus announces start of KU-046 Phase I study in Alzheimer's

Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.

3 Jan 2013

Medical Condition News

The Joint Commission, AHA/ASA recognize HUP with Comprehensive Stroke Center Certification

Scientists demonstrate importance of Plvap gene in mammalian physiology

Top-line results from Biogen Idec’s dexpramipexole Phase 3 trial on amyotrophic lateral sclerosis

Pfizer, Repligen sign licensing deal to advance spinal muscular atrophy program

Researchers analyze impact of 3 unexpected sex determination factors

FDA approves Abbott’s XIENCE Xpedition Everolimus Eluting Coronary Stent System

Celtaxsys commences CTX-4430 Phase 1 study to treat pulmonary inflammation

FDA clears Soft Tissue Regeneration’s STR GRAFT

Partin Tables to predict prostate cancer spread now updated

Itch-specific nerve cells in skin discovered by John Hopkins scientists

Trovagene, MD Anderson partner to detect transrenal BRAF mutations in metastatic cancers

A little extra fat could be protective

Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

18F-FDG PET/CT may become important distant staging modality in patients with breast cancer

Aerobic better than resistance training when it comes to weight and fat loss

Psychiatric patients at risk of hospitalization due to protected records

Gut bacterial communities play an integral role in protecting against human intestinal disorders

No significant difference in patient outcomes with RBC transfusions using lower threshold levels

Improving research on BPA chemical may lead to better guidelines for human health

Kareus announces start of KU-046 Phase I study in Alzheimer's

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Latest News